CR20110513A - Biomarcador para monitorear pacientes - Google Patents

Biomarcador para monitorear pacientes

Info

Publication number
CR20110513A
CR20110513A CR20110513A CR20110513A CR20110513A CR 20110513 A CR20110513 A CR 20110513A CR 20110513 A CR20110513 A CR 20110513A CR 20110513 A CR20110513 A CR 20110513A CR 20110513 A CR20110513 A CR 20110513A
Authority
CR
Costa Rica
Prior art keywords
biomarcator
monitor patients
immunotherapy
patients
monitor
Prior art date
Application number
CR20110513A
Other languages
English (en)
Inventor
Bruce Acres
Original Assignee
Ifco Systems Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifco Systems Gmbh filed Critical Ifco Systems Gmbh
Publication of CR20110513A publication Critical patent/CR20110513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención es en el campo de la inmunoterapia y se refiere a métodos para determinar la eficacia de ciertos tratamientos de inmunoterapia.
CR20110513A 2009-04-17 2011-09-29 Biomarcador para monitorear pacientes CR20110513A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09305328 2009-04-17

Publications (1)

Publication Number Publication Date
CR20110513A true CR20110513A (es) 2012-01-06

Family

ID=42270292

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110513A CR20110513A (es) 2009-04-17 2011-09-29 Biomarcador para monitorear pacientes

Country Status (27)

Country Link
US (2) US20120058493A1 (es)
EP (1) EP2419728B1 (es)
JP (1) JP5661738B2 (es)
KR (1) KR20120027146A (es)
CN (1) CN102395883B (es)
AU (1) AU2010237215B2 (es)
BR (1) BRPI1010512A2 (es)
CA (1) CA2759050A1 (es)
CO (1) CO6440591A2 (es)
CR (1) CR20110513A (es)
CY (1) CY1114910T1 (es)
DK (1) DK2419728T3 (es)
ES (1) ES2445146T3 (es)
HK (1) HK1163246A1 (es)
HR (1) HRP20140262T1 (es)
IL (1) IL214917A (es)
MX (1) MX2011010920A (es)
NZ (1) NZ594896A (es)
PL (1) PL2419728T3 (es)
PT (1) PT2419728E (es)
RU (1) RU2555340C2 (es)
SG (1) SG175060A1 (es)
SI (1) SI2419728T1 (es)
SM (1) SMT201400046B (es)
TW (1) TWI426270B (es)
WO (1) WO2010119003A1 (es)
ZA (1) ZA201107545B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6375947B2 (ja) * 2012-05-11 2018-08-22 味の素株式会社 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
WO2019113449A1 (en) * 2017-12-08 2019-06-13 Stc.Unm In vivo imaging of tumor infiltration leukocytes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE19520606B4 (de) 1995-06-06 2004-04-08 Roche Diagnostics Gmbh Vorrichtung zur optischen Untersuchung von Oberflächen
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU727308B2 (en) 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
WO2000046355A2 (en) 1999-02-04 2000-08-10 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
FR2773885B1 (fr) 1998-01-16 2000-03-03 Elf Antar France Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
JP3119228B2 (ja) 1998-01-20 2000-12-18 日本電気株式会社 液晶表示パネル及びその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2004011082A1 (en) 2002-07-26 2004-02-05 Myomend, Inc. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
DK1896051T3 (en) * 2005-06-28 2015-01-05 Oncothyreon Inc PROCESS FOR THE TREATMENT OF PATIENTS WITH A mucinous glycoprotein (MUC1) vaccine
AU2007327807A1 (en) * 2006-12-05 2008-06-12 Transgene S.A. Means and method for raising improved immune response
AU2009259699B2 (en) * 2008-05-29 2014-01-23 Transgene Sa Biomarker for selecting patients and related methods

Also Published As

Publication number Publication date
SG175060A1 (en) 2011-11-28
ZA201107545B (en) 2012-07-25
KR20120027146A (ko) 2012-03-21
MX2011010920A (es) 2011-11-04
SI2419728T1 (sl) 2014-03-31
TWI426270B (zh) 2014-02-11
ES2445146T3 (es) 2014-02-28
CY1114910T1 (el) 2016-12-14
HK1163246A1 (en) 2012-09-07
DK2419728T3 (da) 2014-02-03
JP2012524248A (ja) 2012-10-11
CN102395883B (zh) 2015-12-02
IL214917A (en) 2016-03-31
US20140141039A1 (en) 2014-05-22
WO2010119003A1 (en) 2010-10-21
EP2419728B1 (en) 2014-01-08
RU2011146419A (ru) 2013-05-27
CN102395883A (zh) 2012-03-28
IL214917A0 (en) 2011-11-30
CO6440591A2 (es) 2012-05-15
EP2419728A1 (en) 2012-02-22
CA2759050A1 (en) 2010-10-21
PT2419728E (pt) 2014-03-12
JP5661738B2 (ja) 2015-01-28
TW201040530A (en) 2010-11-16
SMT201400046B (it) 2014-05-07
BRPI1010512A2 (pt) 2016-03-15
US20120058493A1 (en) 2012-03-08
RU2555340C2 (ru) 2015-07-10
HRP20140262T1 (hr) 2014-04-25
NZ594896A (en) 2013-07-26
PL2419728T3 (pl) 2014-05-30
AU2010237215A1 (en) 2011-09-22
AU2010237215B2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
CU20140025A7 (es) Pirimidinas anilladas sustituidas
BR112012000934A2 (pt) cassetes e métodos de utilizacao destes
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
UY33271A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
CR20130517A (es) Tratamientos combinados para neoplasias hematológicas malignas
CR20110560A (es) Métodos de tratamiento para tumores sólidos
EP2560681A4 (en) USE OF TAU FOR MONITORING IMMUNOTHERAPY
BR112013029079A2 (pt) dispositivo de rompimento do tecido e métodos correspondentes
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
EP2385843A4 (en) TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
CR20120473A (es) Composiciones y métodos para el diagnóstico y tratamiento de tumores
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
UY33272A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
UY33754A (es) Monobactamas
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BR112014006291A2 (pt) composição e utilização da composição
CY1118091T1 (el) Ανοσολογικως χρησιμα αλατα αργινινης
EA201201296A1 (ru) Способы лечения диабетических язв стопы
BR112014012495A2 (pt) método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
IL236637A (en) Diploorulctam Compounds as selective ep4 receptor agonists for use in ep4-mediated diseases and conditions
BR112014011488A2 (pt) medicamento para tratamento terapêutico e/ou melhora de sépsis